EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study

Samantha E Jacobs iD, Uroosa Ibrahim, Akasha Barreto Vega, Jonathan Lagdameo, Jacquelyn Callahan, Usha Govindarajulu, Melissa Gitman, John E Levine, Meenakshi Rana, Alla Keyzner

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14290 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Samantha E Jacobs und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Flow Cytometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Eurofins Viracor, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus‐specific T‐cell‐mediated immunity (CMV‐CMI) protects from CMV infection in allogeneic hematopoietic cell transplantation (allo‐HCT), but to date, there is no validated measure of CMV immunity for this population.

Methods

In this prospective, observational, pilot study, CMV T‐cell responses were evaluated monthly and at onset of graft‐versus‐host disease (GVHD) or CMV infection in CMV‐seropositive allo‐HCT recipients using a commercial flow cytometry assay, the CMV inSIGHT T‐Cell Immunity Panel (CMV‐TCIP). The primary endpoint was the time to first positive CMV‐TCIP, defined as percentage of interferon‐γ‐producing CD4+ or CD8+ CMV‐specific T cells >0.2%. Letermovir was prescribed from day +10 to ≥100.

Results

Twenty‐eight allo‐HCT recipients were enrolled. The median time to first positive CMV‐TCIP result was earlier for CD4+ (60 days [interquartile range, IQR 33‒148]) than for CD8+ T cells (96 days [IQR 33‒155]) and longer for haploidentical and mismatched transplant recipients (77 and 96 days, respectively) than for matched donors (45 and 33 days, respectively). CD4+ and CD8+ CMV‐CMI recovery was sustained in 10/10 (100%) and 10/11 (91%) patients, respectively, without GVHD, whereas CD4+ and/or CD8+ CMV‐CMI was lost in 4/6 and 2/6 patients, respectively, with GVHD requiring steroids. As a predictor of clinically significant CMV infection in patients with low‐level CMV reactivation, the sensitivity and negative predictive value of CMV‐TCIP were 90% and 87.5%, respectively, for CD4+ CMV‐TCIP and 66.7% and 62.5%, respectively, for CD8+ CMV‐TCIP.

Conclusions

There was significant variability in time to CMV‐CMI recovery post‐HCT, with slower recovery after haploidentical and mismatched HCT. CD4+ CMV‐CMI may protect against CS‐CMVi, but immunity may be lost with GVHD diagnosis and treatment. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsCytomegalovirusFlow CytometryGraft vs Host DiseaseCD8-Positive T-LymphocytesCD4-Positive T-LymphocytesTransplantation, HomologousHumansPilot ProjectsMiddle AgedMaleProspective StudiesFemaleAdultAgedImmunity, CellularAntiviral Agents

Stichwörter der Autor:innen

T‐cell immunitycytomegalovirusstem cell transplantviral infection

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Samantha E Jacobs

Förderung

  • Eurofins Viracor, LLC

Zitieren

APA

Jacobs, S. E., Ibrahim, U., Vega, A. B., Lagdameo, J., Callahan, J., Govindarajulu, U., Gitman, M., Levine, J. E., Rana, M., & Keyzner, A. (2024). Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study. Transplant Infectious Disease. https://doi.org/10.1111/tid.14290

Vancouver

Jacobs SE, Ibrahim U, Vega AB, Lagdameo J, Callahan J, Govindarajulu U, et al. Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study. Transplant Infectious Disease. 2024. doi:10.1111/tid.14290

BibTeX
@article{Jacobs2024,
  author = {Jacobs, Samantha E and Ibrahim, Uroosa and Vega, Akasha Barreto and Lagdameo, Jonathan and Callahan, Jacquelyn and Govindarajulu, Usha and Gitman, Melissa and Levine, John E and Rana, Meenakshi and Keyzner, Alla},
  title = {Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14290}
}
Kostenlos starten →